Working… Menu

Use of Armodafinil for Fatigue in Sarcoidosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00555347
Recruitment Status : Completed
First Posted : November 8, 2007
Last Update Posted : May 27, 2015
Information provided by (Responsible Party):
Robert P Baughman, University of Cincinnati

Brief Summary:
To determine the effect of Armodafinil (Nuvigil) on fatigue and sleep in sarcoidosis.

Condition or disease Intervention/treatment Phase
Sarcoidosis Fatigue Sleepiness Drug: Armodafinil Drug: Placebo Phase 2 Phase 3

Detailed Description:

The study will be divided into two halves. Patients will receive either drug or placebo in the first half. Patients receiving active drug will be started at one dose and it can be increased at the second visit. Those patients randomized to placebo will also have their dose adjusted by the investigating physician. The physicians will be blinded as to whether the patient is receiving drug or placebo. In the second half of the study, patients will receive the opposite treatment.

Patients will have complete detailed questionnaires regarding their fatigue, sleepiness, and overall quality of life.

They will have sleep studies done at the start and after each half of the study to determine the effect of therapy on sleepiness.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Use of Armodafinil (R-modafinil) for Fatigue in Sarcoidosis
Study Start Date : October 2007
Actual Primary Completion Date : August 2010
Actual Study Completion Date : August 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fatigue Sarcoidosis
Drug Information available for: Armodafinil

Arm Intervention/treatment
Active Comparator: Armnodafinil
Drug: Armodafinil
Dosage 150-250 mg
Other Name: Nuvigil

Placebo Comparator: Placebo Drug: Placebo

Primary Outcome Measures :
  1. To determine the effect of Armodafinil (Nuvigil) on fatigue and sleep in sarcoidosis. [ Time Frame: Prospective ]

Secondary Outcome Measures :
  1. To determine the effect of Armodafinil (Nuvigil) on pulmonary function in sarcoidosis. [ Time Frame: Prospective ]
  2. To determine the safety and tolerability of Armodafinil (Nuvigil) in sarcoidosis. [ Time Frame: Prospective ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of sarcoidosis using standard criteria 15.
  • Disease for more than one year
  • On stable, systemic therapy
  • Complain of fatigue which has been present for more than six months.
  • Over 18 years of age
  • Provide written informed consent.

Exclusion Criteria:

  • Pregnancy
  • Change in therapy for sarcoidosis in prior three months
  • History of ventricular arrythmias

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00555347

Layout table for location information
United States, Ohio
University of Cincinnati
Cincinnati, Ohio, United States, 45267
Sponsors and Collaborators
University of Cincinnati
Layout table for investigator information
Principal Investigator: Robert P Baughman, MD University of Cincinnati
Layout table for additonal information
Responsible Party: Robert P Baughman, Prof Medicine, University of Cincinnati Identifier: NCT00555347    
Other Study ID Numbers: IRB 07011901
First Posted: November 8, 2007    Key Record Dates
Last Update Posted: May 27, 2015
Last Verified: April 2013
Keywords provided by Robert P Baughman, University of Cincinnati:
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoproliferative Disorders
Lymphatic Diseases
Central Nervous System Stimulants
Physiological Effects of Drugs
Wakefulness-Promoting Agents
Cytochrome P-450 CYP3A Inducers
Cytochrome P-450 Enzyme Inducers
Molecular Mechanisms of Pharmacological Action